Who owns Abivax S.A. (ABVX)? Elite investor 13F holders
4 tracked elite investors reported holding Abivax S.A as of 2026-06-30, including Caligan Partners, Tudor Investment, D.E. Shaw, Maverick Capital. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
4 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Caligan Partners | ABIVAX SA | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 207608952.00 USD | 1557924.000000 | Shares | add | Original filing |
| Tudor Investment | ABIVAX SA | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 24964262.00 USD | 187335.000000 | Shares | add | Original filing |
| D.E. Shaw | ABIVAX SA | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 12040974.00 USD | 90357.000000 | Shares | add | Original filing |
| Maverick Capital | ABIVAX SA | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 5330400.00 USD | 40000.000000 | Shares | buy | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.